New hope for frail lung cancer patients: targeted drug repotrectinib under study
NCT ID NCT06552234
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests a drug called repotrectinib in 30 frail or elderly patients with advanced lung cancer that has a specific genetic change (ROS1). The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug by mouth, and doctors monitor their response every two months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HM
RECRUITINGMarseille, Bouches Du Rhône, France
-
CH Aix-en-Provence
RECRUITINGAix-en-Provence, Bouches Du Rhône, France
-
CH Chambéry
RECRUITINGChambéry, France
-
CH Cornouaille
RECRUITINGQuimper, France
-
CHD Vendée
RECRUITINGLa Roche-sur-Yon, France
-
CHI Créteil
RECRUITINGCréteil, France
-
CHRU Lille
RECRUITINGLille, France
-
CHU Angers
RECRUITINGAngers, France
-
CHU Bordeaux
RECRUITINGBordeaux, France
-
CHU Brest
RECRUITINGBrest, France
-
CHU Limoges
RECRUITINGLimoges, France
-
CHU Rennes
RECRUITINGRennes, France
-
CHU Rouen
RECRUITINGRouen, France
-
CHU Toulouse
RECRUITINGToulouse, France
-
Centre François Baclesse
RECRUITINGCaen, France
-
HIA Sainte Anne
RECRUITINGToulon, Var, France
-
Hospices Civils de Lyon
RECRUITINGLyon, France
-
Hôpital Foch
RECRUITINGSuresnes, France
-
Hôpitaux Nord-Ouest
RECRUITINGVillefranche-sur-Saône, France
-
Hôpitaux civils de Colmar
RECRUITINGColmar, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- New immunotherapy combo aims to improve lung cancer outcomes
- New antibody drug targets Cancer-Related fluid in the lungs
- New drug cocktail shows promise for Hard-to-Treat lung cancer
- Can a tailored drug cocktail beat lung cancer recurrence?
- New hope for drug-resistant lung cancer: combo therapy enters trial